ALLInBio

Executive Summary

ALLInBio is a privately-held biotechnology company pioneering a precision immunology approach to treat chronic inflammatory diseases. Founded in 2020 and based in San Francisco, the company aims to shift the current treatment paradigm from symptom management to early, targeted intervention by identifying genetically predisposed 'at-risk' populations. By selecting patients who are likely to progress to severe disease, ALLInBio intends to address the root cause of inflammation and potentially halt disease progression before irreversible damage occurs. The company's platform leverages AI and machine learning to analyze genetic and biomarker data, enabling the discovery and development of biologics and drug delivery systems tailored to specific patient subsets. This precision strategy could significantly improve outcomes in indications such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis, where heterogeneity in patient response remains a major challenge. As a private entity with undisclosed funding and an early-stage pipeline, ALLInBio's progress is closely watched by investors and clinicians interested in the convergence of AI and immunology. The company's focus on early intervention in genetically defined populations positions it at the forefront of preventive medicine in chronic inflammation. While no clinical-stage assets have been publicly disclosed, the preclinical platform and strategic approach suggest potential for significant impact if validated in humans. Upcoming catalysts include the initiation of a first-in-human study for its lead candidate, presentation of preclinical data at a major immunology conference, and potential series A financing to support pipeline advancement. The company's success hinges on translating its precision immunology concept into clinical proof-of-concept and establishing partnerships for further development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead Candidate60% success
• Q3 2026Presentation of Preclinical Data at Major Immunology Conference80% success
• Q2 2026Series A Funding Announcement70% success